A Randomized Phase 2 Open-Label Study of IMC-A12, as a Single Agent or in Combination With Cetuximab, in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck and Disease Progression on Prior Platinum-Based Chemotherapy.
Phase of Trial: Phase II
Latest Information Update: 31 May 2013
At a glance
- Drugs Cixutumumab (Primary) ; Cetuximab
- Indications Head and neck cancer
- Focus Biomarker; Therapeutic Use
- 31 May 2013 Primary endpoint 'Progression-free-survival-duration' has not been met.
- 31 May 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
- 13 Aug 2012 Actual end date (1 Jul 2012) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History